全球凝血测试,血栓生成和粘弹性测试的有用性,用于评估罕见的凝血因子缺陷中的出血表型
Tim Dreier1, Dino Mehic1, Johanna Gebhart1
1Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Hamostaseologie
|October 15, 2025
概括
全球凝血测试,如血栓生成试验,等离子体生成试验和ROTEM在评估罕见因子缺乏症的出血严重程度方面表现有前途. 这些测试可能有助于分层患者,并预测主要出血风险.
科学领域:
- 血液学 血液学 血液学
- 凝血障碍 凝血障碍 凝血障碍
- 诊断检测试验 诊断检测试验
背景情况:
- 罕见的遗传凝血因子缺陷,具有可变的出血表型.
- 传统的静血测试往往无法充分预测临床出血严重程度.
- 有限的临床经验和因子水平与症状之间的不良相关性使疾病管理复杂化.
研究的目的:
- 评估全球凝血试验在评估罕见凝血因子缺陷严重性的有用性.
- 为了确定全球凝血测试结果与临床出血症状之间的相关性.
主要方法:
- 关于血栓生成试验 (TGA),等离子体生成试验 (PGA) 和旋转血栓形成显微镜 (ROTEM) 的文献综述.
- 在各种罕见的凝血因子缺陷中分析TGA,PGA和ROTEM表现.
- 测定结果与临床出血严重程度和因子水平的相关性.
主要成果:
- 在罕见的凝血因子缺乏症中,血栓生成,等离子体生成和ROTEM通常受到损害.
- 血栓生成减少与出血严重程度相关,在血栓前,V,VII,X和XI因子缺乏的情况下.
- ROTEM参数区分无症状和出血的患者与FX,FXI和纤维素素缺乏.
- PGA损伤与出血严重程度没有一致的相关性.
结论:
- 全球凝血测试 (TGA,PGA,ROTEM) 显示了在罕见的因子缺乏症中分层出血严重性的潜力.
- 这些测试可以帮助评估主要出血并发症的风险.
- 需要进一步的前性研究,采用更大的样本大小来验证这些发现.
相关概念视频
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
289
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
289
Coagulation
9.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.6K


